Rotavirus gastroenteritis in children less than five years of age in primary care settings in Bulgaria: an observational study.
BACKGROUND
Rotavirus (RV) causes a high proportion of acute gastroenteritis (AGE) cases, especially among children under the age of five years old. This surveillance study was undertaken to study the incidence and severity of rotavirus gastroenteritis (RVGE) in primary care settings in Bulgaria over a one-year period.


METHODS
In this prospective, observational study of AGE cases in children under five years of age presenting in the primary care setting over a one year period, stool samples were collected and tested for RV using a rapid visual immunochromatographic test kit. After the first visit, parents monitored their child for about two weeks and reported the symptoms experienced by the child during the follow-up period to the physician in a follow-up phone call. The percentage of RVGE cases among AGE was calculated and the severity of AGE (according to the 20-point Vesikari scale) was assessed by the physician based on the symptoms reported by the parents. The seasonality of RVGE was also studied.


RESULTS
The proportion of RVGE among the 624 AGE cases examined was 25.5%. Severe AGE was experienced by 81.8% RV-positive and 54.6% RV-negative children (p-value <0.001) and a third of all severe AGE cases occurred in RV-positive patients. A multivariate logistic regression analysis of the determinants of hospitalization indicated that severity of disease and RV-positivity were the statistically significant variables explaining hospitalization of AGE cases; even controlling for severity, RV-positive patients were more often hospitalized than RV-negative ones. RVGE cases occurred throughout the year, with peaks during August and September.


CONCLUSIONS
Our study emphasizes that RV is an important cause of AGE in children under five presenting in primary care settings in Bulgaria and a disproportionately high proportion of severe AGE cases may be attributed to RV infections.


BACKGROUND
NCT01733849.
MD, Department of Infectious Diseases, Medical University Sofia, Bulgaria.
Mayda
M
Tiholova
GSK Pharmaceuticals Ltd., Bangalore, India.
Kusuma
K
Gopala
MD, GSK Bulgaria, Sofia, Bulgaria.
Magda
M
Berberova
MD, GSK Bulgaria, Sofia, Bulgaria.
Margarita
M
Strokova-Stoilova
MD, MPH, GSK Vaccines, Wavre, Belgium.
Monica
M
Tafalla
RV disease burden; Rotavirus; acute gastroenteritis; primary care settings